A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors
Latest Information Update: 04 Nov 2024
Price :
$35 *
At a glance
- Drugs WJ 47156 (Primary) ; Bevacizumab; Toripalimab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 31 Oct 2024 Status changed from not yet recruiting to recruiting.
- 02 Sep 2024 New trial record